Metabolic diseases present substantial health challenges globally. The identification of innovative therapies through understanding the underlying mechanisms and pathways involved is crucial to combat these conditions.  

At Evotec our expertise in metabolic disorders is built through more than 20 years of research including conditions such as, diabetes, obesity, kidney disease, liver disease (NAFLD, NASH), and muscle disease (muscular dystrophy). Our experience covers a wide range of target classes, such as GPCRs, ion channels, transporters, and enzymes.

Our expert teams dive deep into the science of your metabolic disease target or therapeutic focus area to design complete multi-modality drug discovery approaches ranging from target validation to preclinical candidate development stages.

We provide a comprehensive portfolio of translational models and read-outs that maximize the chances of developing novel therapeutics.

• Functional disease-relevant in vitro assays are set up in high-throughput screening compatible immortalized cell lines, primary human and rodent cells. Ex vivo assays with tissues derived from animal disease models are also available. All relevant target tissues are covered such as pancreatic islets, adipose tissue, skeletal muscle, kidney, and liver.
• In vivo animal models (mouse, rat) generated from disease-specific genetic strains or from diet-induced origin complement the cellular assay cascade during Lead Optimization stages.